Medicare GLP-1 Bridge Program Launches to Improve Obesity Treatment Access
Explore the new Medicare GLP-1 Bridge program enhancing weight management access for seniors. Affordable options start July 1, 2026.
Nutritional Guidance in GLP-1 Therapy for Weight Management
Explore the importance of nutritional guidance alongside GLP-1 medications for effective weight management and sustainable health outcomes.
GLP-1 Receptor Agonists: A Breakthrough in Cardiovascular Health
Discover the breakthrough role of GLP-1 receptor agonists in cardiovascular health, FDA-approved for patients managing diabetes and obesity.
Federal Move to Cut Obesity Drug Prices Expands Medicare Coverage
The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.
Trump Administration Proposes Medicare Pilot for GLP-1 Weight Loss Drug Coverage
Trump administration proposes a Medicare and Medicaid pilot to cover GLP-1 weight loss drugs, highlighting access benefits alongside fraud and regulatory oversight challenges.
Novo Nordisk Expands Wegovy Access with New Pricing and Legal Actions
Novo Nordisk expands access to Wegovy with a new self-pay pricing program and pursues legal actions against unauthorized compounded drug sales, impacting the obesity treatment market.